Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Subcutaneous Durvalumab in Patients With Non-Small Cell and Small Cell Lung Cancer - SCope-D1

NCT04870112 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04870112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04870112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Subcutaneous Durvalumab in Patients With Non-Small Cell and Small Cell Lung Cancer - SCope-D1
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Terminated
Start date
June 28, 2021
Completion date
August 30, 2023
Enrollment
18 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, small cell lung cancer